Early Introduction of Egg for Infants with Atopic Dermatitis to Prevent Egg Allergy: A Double-Blind Placebo-Controlled Randomized Clinical Trial
Saturday, March 5, 2016: 2:30 PM
Room 408B (Convention Center)
Osamu Natsume, MD, , , , , , , , , , , ,

We investigated whether an early introduction of a small amount of egg for infants with atopic dermatitis would prevent egg allergy in the first year of life.


This intervention was carried out as a double-blind, placebo-controlled, parallel-group, randomized clinical trial (DBPCRCT). Infants with atopic dermatitis were randomly assigned to one of the two groups: placebo or egg consumption. The infants were enrolled between four to five months of age, and started taking egg powder or placebo daily from six months until 12 months of age. Participants of the intervention arm (egg group) took 50 mg of heated egg powder from six to nine months and 250 mg from nine to 12 months of age. The primary outcome was a prevalence of hen’s egg allergy confirmed by oral food challenges at 12 months of age.


This trial was completed based on the result of a scheduled interim analysis which showed a significant difference between the two groups. A total of 121 participants were in the intention-to-treat analysis (placebo group n=61; egg group n=60). The prevalence of egg allergy was 37.7% in placebo group and 8.3% in egg group (p=0.0013). There was no significant difference in adverse events between the two groups.


The introduction of a small amount of heated egg at six months old followed by stepwise increasing in intake is effective and safe for infants with atopic dermatitis to prevent hen’s egg allergy in the first year of life. The trial registration is UMIN-CTR 000008673.